RBC Capital raised the firm’s price target on CorMedix to $10 from $6 and keeps an Outperform rating on the shares. The company reported Q3 “with optimism” heading into its key DefenCath PDUFA in catheter-related blood stream infections prevention in hemodialysis, the analyst tells investors in a research note. All signals appeared positive on the prospects of an approval outcome, which is now seen as increasingly likely this time around, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRMD:
- CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
- CorMedix reports Q3 EPS (17c), consensus (21c)
- CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
- CorMedix options imply 36.0% move in share price post-earnings
- CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
